{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "07",
                "@timestamp": "2023-03-07T18:38:41.000041-05:00",
                "@year": "2023",
                "@month": "03"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2020",
                "@month": "12"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {"xocs:funding-agency-matched-string": "American Society of Clinical Oncology, Society for Immunotherapy of Cancer"},
                {"xocs:funding-agency-matched-string": "Fate Therapeutics"},
                {
                    "xocs:funding-agency-matched-string": "National Institutes of Health National Cancer Institute",
                    "xocs:funding-id": "K08 CA241400"
                },
                {
                    "xocs:funding-agency-acronym": "NCI",
                    "xocs:funding-agency": "National Cancer Institute",
                    "xocs:funding-id": [
                        {"$": "K08CA241400"},
                        {"$": "P30CA006516"},
                        {"$": "P30CA008748"}
                    ],
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000054",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001"
                },
                {
                    "xocs:funding-agency-matched-string": "Lymphoma Research Foundation",
                    "xocs:funding-agency-acronym": "LRF",
                    "xocs:funding-agency": "Lymphoma Research Foundation",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100001219",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "American Society of Hematology",
                    "xocs:funding-agency-acronym": "ASH",
                    "xocs:funding-agency": "American Society of Hematology",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100001422",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Leukemia Lymphoma Society",
                    "xocs:funding-agency-acronym": "LLS",
                    "xocs:funding-agency": "Leukemia and Lymphoma Society",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100005189",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Bristol Myers Squibb",
                    "xocs:funding-agency-acronym": "BMS",
                    "xocs:funding-agency": "Bristol-Myers Squibb Canada",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100008021",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6251999/"
                },
                {
                    "xocs:funding-agency-matched-string": "Dana-Farber/Harvard Cancer Center Support",
                    "xocs:funding-agency-acronym": "DF/HCC",
                    "xocs:funding-agency": "Dana-Farber/Harvard Cancer Center",
                    "xocs:funding-id": "P30 CA006516",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100008126",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Parker Institute for Cancer Immunotherapy",
                    "xocs:funding-agency": "Parker Institute for Cancer Immunotherapy",
                    "xocs:funding-id": "P30 CA008748",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100014547",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2023-03-17T01:38:45.755703Z",
            "xocs:funding-text": [
                {"$": "S.M. has received research support from Takeda Oncology, Bristol Myers Squibb, Janssen Pharmaceuticals, and Allogene Therapeutics, as well as honoraria from Physicians\u2019 Education Resource. E.L.S. reports licensed patents/royalties regarding CAR T-cell therapy for MM, has received research funding from Bristol Myers Squibb, and has acted as a paid consultant for Bristol Myers Squibb, Fate Therapeutics, and Precision Biosciences. K.W. declares no competing financial interests."},
                {"$": "K.W. receives salary support from the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. S.M. acknowledges support from Memorial Sloan Kettering Core Grant P30 CA008748. E.L.S. acknowledges support from the National Institutes of Health National Cancer Institute (K08 CA241400), American Society of Hematology, Leukemia Lymphoma Society, Lymphoma Research Foundation, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Multiple Myeloma Research Foundation and Dana-Farber/Harvard Cancer Center Support Grant (P30 CA006516)."}
            ],
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2010398061-d0bfd002ed7fc63c086d5d105db34b75",
                            "ce:source-text": "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;",
                            "@dptid": "109501192"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@author-instance-id": "2010398061-d7a25d8a02d7e8516a087bd5557b10ae",
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60028190",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Research Unit in Translational Hematology"},
                                {"$": "Department of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60028190",
                                "@dptid": "113019942"
                            },
                            "@affiliation-instance-id": "2010398061-36cb8acc824bb373bc07ca5ff5f6be71",
                            "ce:source-text": "Research Unit in Translational Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand;",
                            "@dptid": "113019942"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@author-instance-id": "2010398061-d7a25d8a02d7e8516a087bd5557b10ae",
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Myeloma Service"},
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2010398061-8f93dce1c5fa91d5fc615b59f1bb1442",
                            "ce:source-text": "Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;",
                            "@dptid": "109501192"
                        },
                        "author": [{
                            "ce:given-name": "Sham",
                            "preferred-name": {
                                "ce:given-name": "Sham",
                                "ce:initials": "S.",
                                "ce:surname": "Mailankody",
                                "ce:indexed-name": "Mailankody S."
                            },
                            "@author-instance-id": "2010398061-4ff00c9b572e56db1c4ccc0a987fb5be",
                            "@seq": "2",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mailankody",
                            "@auid": "36008881400",
                            "ce:indexed-name": "Mailankody S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Cellular Therapeutics Center"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "119752309"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2010398061-93da8d3a290f4e86280eb58876b91074",
                            "ce:source-text": "and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY;",
                            "@dptid": "119752309"
                        },
                        "author": [{
                            "ce:given-name": "Sham",
                            "preferred-name": {
                                "ce:given-name": "Sham",
                                "ce:initials": "S.",
                                "ce:surname": "Mailankody",
                                "ce:indexed-name": "Mailankody S."
                            },
                            "@author-instance-id": "2010398061-4ff00c9b572e56db1c4ccc0a987fb5be",
                            "@seq": "2",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mailankody",
                            "@auid": "36008881400",
                            "ce:indexed-name": "Mailankody S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60007997",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Weill Cornell Medical College"}
                            ],
                            "affiliation-id": {
                                "@afid": "60007997",
                                "@dptid": "112748380"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2010398061-a036894edd79c67df6ded21f942b29f9",
                            "ce:source-text": "Department of Medicine, Weill Cornell Medical College, New York, NY",
                            "@dptid": "112748380"
                        },
                        "author": [{
                            "ce:given-name": "Sham",
                            "preferred-name": {
                                "ce:given-name": "Sham",
                                "ce:initials": "S.",
                                "ce:surname": "Mailankody",
                                "ce:indexed-name": "Mailankody S."
                            },
                            "@author-instance-id": "2010398061-4ff00c9b572e56db1c4ccc0a987fb5be",
                            "@seq": "2",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Mailankody",
                            "@auid": "36008881400",
                            "ce:indexed-name": "Mailankody S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002746",
                            "@country": "usa",
                            "city": "Boston",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "Dana-Farber Cancer Institute"},
                                {"$": "Harvard Medical School"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002746",
                                    "@dptid": "113642482"
                                },
                                {"@afid": "60014334"}
                            ],
                            "state": "MA",
                            "@affiliation-instance-id": "2010398061-b0a4126ae197306c4b0ae8e6aed6e59e",
                            "ce:source-text": "Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA",
                            "@dptid": "113642482"
                        },
                        "author": [{
                            "ce:given-name": "Eric L.",
                            "preferred-name": {
                                "ce:given-name": "Eric L.",
                                "ce:initials": "E.L.",
                                "ce:surname": "Smith",
                                "ce:indexed-name": "Smith E.L."
                            },
                            "@author-instance-id": "2010398061-25ae87696020c5be0e70c406c6b398c7",
                            "@seq": "3",
                            "ce:initials": "E.L.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Smith",
                            "@auid": "35448715000",
                            "ce:indexed-name": "Smith E.L."
                        }]
                    }
                ],
                "citation-title": "Future of CAR T cells in multiple myeloma",
                "abstracts": "Â© 2020 American Society of Hematology. All rights reserved.Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall response rates in this difficult-to-treat patient population. However, a significant proportion of patients ultimately relapse despite achieving deep remission. Several innovative approaches, including alternative/dual-antigen-specific CAR T-cell constructs, genetically engineered \u201coff-the-shelf\u201d CAR T cells, and strategies to counteract an immunosuppressive microenvironment, may dramatically reshape the field of CAR T-cell therapy in the future. These strategies are being actively investigated in preclinical and early clinical trial settings with the hopes of enhancing the durability of responses and, thereby, improving the overall survival of RRMM patients after CAR T-cell therapy.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "address-part": "450 Brookline Ave",
                        "postal-code": "02215",
                        "@country": "usa",
                        "city": "Boston",
                        "organization": [
                            {"$": "Department of Medical Oncology"},
                            {"$": "Dana-Farber Cancer Institute"}
                        ],
                        "state": "MA",
                        "ce:source-text": "Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215"
                    },
                    "person": {
                        "ce:given-name": "Eric L.",
                        "ce:initials": "E.L.",
                        "ce:surname": "Smith",
                        "ce:indexed-name": "Smith E.L."
                    }
                },
                "citation-info": {
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "Hematology",
                    "website": {"ce:e-address": {
                        "$": "https://ashpublications.org/hematology/article/2020/1/272/474358/Future-of-CAR-T-cells-in-multiple-myeloma",
                        "@type": "email"
                    }},
                    "@country": "usa",
                    "translated-sourcetitle": {
                        "$": "Hematology",
                        "@xml:lang": "eng"
                    },
                    "issn": [
                        {
                            "$": "15204383",
                            "@type": "electronic"
                        },
                        {
                            "$": "15204391",
                            "@type": "print"
                        }
                    ],
                    "volisspag": {
                        "voliss": {
                            "@volume": "20",
                            "@issue": "1"
                        },
                        "pagerange": {
                            "@first": "272",
                            "@last": "279"
                        }
                    },
                    "@type": "j",
                    "publicationyear": {"@first": "2020"},
                    "publisher": {"publishername": "American Society of Hematology"},
                    "sourcetitle": "Hematology (United States)",
                    "@srcid": "25981",
                    "publicationdate": {
                        "month": "12",
                        "year": "2020",
                        "date-text": "December 2020",
                        "day": "01"
                    }
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "25",
                                    "classification-description": "Hematology"
                                },
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2720"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": {
                        "@source": "nlm",
                        "chemical": {"chemical-name": "Receptors, Chimeric Antigen"}
                    }}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2020 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "In-Process",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "SNEMB"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "05",
                    "@timestamp": "BST 03:28:25",
                    "@year": "2021",
                    "@month": "01"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2010398061",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "633604873",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "930318614",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20201130548",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "33275747",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20203146810",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20204438665",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2020170422",
                            "@idtype": "SNEMB"
                        },
                        {
                            "$": "20200413055926",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85097310758",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85097310758",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "633604873",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "342665399",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1182/HEMATOLOGY.2020000111"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "52",
                "reference": [
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062828886",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "2266",
                                    "@last": "2275"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "UH",
                                        "@_fa": "true",
                                        "ce:surname": "Gandhi",
                                        "ce:indexed-name": "Gandhi UH"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "RF",
                                        "@_fa": "true",
                                        "ce:surname": "Cornell",
                                        "ce:indexed-name": "Cornell RF"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Lakshman",
                                        "ce:indexed-name": "Lakshman A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048-2060.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84877087137",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "19",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "2048",
                                    "@last": "2060"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "RO",
                                        "@_fa": "true",
                                        "ce:surname": "Carpenter",
                                        "ce:indexed-name": "Carpenter RO"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MO",
                                        "@_fa": "true",
                                        "ce:surname": "Evbuomwan",
                                        "ce:indexed-name": "Evbuomwan MO"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Pittaluga",
                                        "ce:indexed-name": "Pittaluga S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048-2060."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18): 1726-1737.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85065137503",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "380",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "1726",
                                    "@last": "1737"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Raje",
                                        "ce:indexed-name": "Raje N"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Berdeja",
                                        "ce:indexed-name": "Berdeja J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y",
                                        "@_fa": "true",
                                        "ce:surname": "Lin",
                                        "ce:indexed-name": "Lin Y"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18): 1726-1737."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. 2020; 38(15 suppl):8503.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85086705331",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "8503"}
                            },
                            "ref-text": "(suppl)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "NC",
                                        "@_fa": "true",
                                        "ce:surname": "Munshi",
                                        "ce:indexed-name": "Munshi NC"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "LD",
                                        "@_fa": "true",
                                        "ce:surname": "Anderson",
                                        "ce:indexed-name": "Anderson LD"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results"
                        },
                        "ce:source-text": "Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. 2020; 38(15 suppl):8503."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Mailankody S, Htut M, Lee KP, et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Blood. 2018;132(-suppl 1):957.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062369142",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "132"},
                                "pagerange": {"@first": "957"}
                            },
                            "ref-text": "(-suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Mailankody",
                                        "ce:indexed-name": "Mailankody S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Htut",
                                        "ce:indexed-name": "Htut M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "KP",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee KP"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Mailankody S, Htut M, Lee KP, et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Blood. 2018;132(-suppl 1):957."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Green DJ, Pont M, Sather BD, et al. Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood. 2018;132(suppl 1):1011.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062330323",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "132"},
                                "pagerange": {"@first": "1011"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DJ",
                                        "@_fa": "true",
                                        "ce:surname": "Green",
                                        "ce:indexed-name": "Green DJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Pont",
                                        "ce:indexed-name": "Pont M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "BD",
                                        "@_fa": "true",
                                        "ce:surname": "Sather",
                                        "ce:indexed-name": "Sather BD"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Green DJ, Pont M, Sather BD, et al. Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood. 2018;132(suppl 1):1011."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (r/r mm). Blood. 2019;134(suppl 1):577.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (r/r mm)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082193646",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "577"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Madduri",
                                        "ce:indexed-name": "Madduri D"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "SZ",
                                        "@_fa": "true",
                                        "ce:surname": "Usmani",
                                        "ce:indexed-name": "Usmani SZ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Jagannath",
                                        "ce:indexed-name": "Jagannath S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (r/r mm). Blood. 2019;134(suppl 1):577."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Berdeja JG, Alsina M, Shah ND, et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy. Blood. 2019;134(suppl 1):927.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084125808",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "927"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JG",
                                        "@_fa": "true",
                                        "ce:surname": "Berdeja",
                                        "ce:indexed-name": "Berdeja JG"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Alsina",
                                        "ce:indexed-name": "Alsina M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "ND",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah ND"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Berdeja JG, Alsina M, Shah ND, et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy. Blood. 2019;134(suppl 1):927."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Wang B-Y, Zhao W-H, Liu J, et al. Long-term follow-up of a phase 1, first-inhuman open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134(suppl 1):579.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Long-term follow-up of a phase 1, first-inhuman open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084147974",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "579"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B-Y",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang B-Y"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W-H",
                                        "@_fa": "true",
                                        "ce:surname": "Zhao",
                                        "ce:indexed-name": "Zhao W-H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu J"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Wang B-Y, Zhao W-H, Liu J, et al. Long-term follow-up of a phase 1, first-inhuman open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134(suppl 1):579."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Schinke C, Hoering A, Wang H, et al. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017;102(8):e313-e316.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85026735377",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "102",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "e313",
                                    "@last": "e316"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Schinke",
                                        "ce:indexed-name": "Schinke C"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Hoering",
                                        "ce:indexed-name": "Hoering A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang H"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Schinke C, Hoering A, Wang H, et al. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017;102(8):e313-e316."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84995917601",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "17",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "e328",
                                    "@last": "e346"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Kumar",
                                        "ce:indexed-name": "Kumar S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B",
                                        "@_fa": "true",
                                        "ce:surname": "Paiva",
                                        "ce:indexed-name": "Paiva B"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "KC",
                                        "@_fa": "true",
                                        "ce:surname": "Anderson",
                                        "ce:indexed-name": "Anderson KC"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28-35.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85013092867",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "28",
                                    "@last": "35"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "NC",
                                        "@_fa": "true",
                                        "ce:surname": "Munshi",
                                        "ce:indexed-name": "Munshi NC"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Avet-Loiseau",
                                        "ce:indexed-name": "Avet-Loiseau H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "AC",
                                        "@_fa": "true",
                                        "ce:surname": "Rawstron",
                                        "ce:indexed-name": "Rawstron AC"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Oncol"
                        },
                        "ce:source-text": "Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28-35."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267-2280.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85050754952",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "2267",
                                    "@last": "2280"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JN",
                                        "@_fa": "true",
                                        "ce:surname": "Brudno",
                                        "ce:indexed-name": "Brudno JN"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I",
                                        "@_fa": "true",
                                        "ce:surname": "Maric",
                                        "ce:indexed-name": "Maric I"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "SD",
                                        "@_fa": "true",
                                        "ce:surname": "Hartman",
                                        "ce:indexed-name": "Hartman SD"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267-2280."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210-2221.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85063630209",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "129",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "2210",
                                    "@last": "2221"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "AD",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen AD"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AL",
                                        "@_fa": "true",
                                        "ce:surname": "Garfall",
                                        "ce:indexed-name": "Garfall AL"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "EA",
                                        "@_fa": "true",
                                        "ce:surname": "Stadtmauer",
                                        "ce:indexed-name": "Stadtmauer EA"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Invest"
                        },
                        "ce:source-text": "Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210-2221."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750): 112-116.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85063595432",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "568",
                                    "@issue": "7750"
                                },
                                "pagerange": {
                                    "@first": "112",
                                    "@last": "116"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Hamieh",
                                        "ce:indexed-name": "Hamieh M"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Dobrin",
                                        "ce:indexed-name": "Dobrin A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Cabriolu",
                                        "ce:indexed-name": "Cabriolu A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nature"
                        },
                        "ce:source-text": "Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750): 112-116."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Timmers M, Roex G, Wang Y, et al. Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front Immunol. 2019;10:1613.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85069529543",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "10"},
                                "pagerange": {"@first": "1613"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Timmers",
                                        "ce:indexed-name": "Timmers M"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Roex",
                                        "ce:indexed-name": "Roex G"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang Y"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Timmers M, Roex G, Wang Y, et al. Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front Immunol. 2019;10:1613."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85063446294",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "485"
                                },
                                "pagerange": {"@first": "eaau7746"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EL",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith EL"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Harrington",
                                        "ce:indexed-name": "Harrington K"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Staehr",
                                        "ce:indexed-name": "Staehr M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "FernÃ¡ndez de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Disc. 2020;",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85096869876",
                                "@idtype": "SGR"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "FernÃ¡ndez de Larrea",
                                        "ce:indexed-name": "Fernandez de Larrea C"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Staehr",
                                        "ce:indexed-name": "Staehr M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "AV",
                                        "@_fa": "true",
                                        "ce:surname": "Lopez",
                                        "ce:indexed-name": "Lopez AV"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Cancer Disc"
                        },
                        "ce:source-text": "FernÃ¡ndez de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Disc. 2020;"
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084720586",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "2283"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E",
                                        "@_fa": "true",
                                        "ce:surname": "Zah",
                                        "ce:indexed-name": "Zah E"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E",
                                        "@_fa": "true",
                                        "ce:surname": "Nam",
                                        "ce:indexed-name": "Nam E"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V",
                                        "@_fa": "true",
                                        "ce:surname": "Bhuvan",
                                        "ce:indexed-name": "Bhuvan V"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Commun"
                        },
                        "ce:source-text": "Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Li C, Mei H, Hu Y, Guo T, Liu L, Jiang H, et al. A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. Blood. 2019;134(suppl 1):930.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084152500",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "930"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li C"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Mei",
                                        "ce:indexed-name": "Mei H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu Y"
                                    },
                                    {
                                        "@seq": "4",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Guo",
                                        "ce:indexed-name": "Guo T"
                                    },
                                    {
                                        "@seq": "5",
                                        "ce:initials": "L",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu L"
                                    },
                                    {
                                        "@seq": "6",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Jiang",
                                        "ce:indexed-name": "Jiang H"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Li C, Mei H, Hu Y, Guo T, Liu L, Jiang H, et al. A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. Blood. 2019;134(suppl 1):930."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10): e521-e529.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85072408131",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "e521",
                                    "@last": "e529"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z",
                                        "@_fa": "true",
                                        "ce:surname": "Yan",
                                        "ce:indexed-name": "Yan Z"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Cao",
                                        "ce:indexed-name": "Cao J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Cheng",
                                        "ce:indexed-name": "Cheng H"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Haematol"
                        },
                        "ce:source-text": "Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10): e521-e529."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Pont MJ, Hill T, Cole GO, et al. Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585-1597.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85074676137",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "1585",
                                    "@last": "1597"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "MJ",
                                        "@_fa": "true",
                                        "ce:surname": "Pont",
                                        "ce:indexed-name": "Pont MJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Hill",
                                        "ce:indexed-name": "Hill T"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "GO",
                                        "@_fa": "true",
                                        "ce:surname": "Cole",
                                        "ce:indexed-name": "Cole GO"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Pont MJ, Hill T, Cole GO, et al. Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585-1597."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Laurent SA, Hoffmann FS, Kuhn PH, et al. Î³-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):7333.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Î³-Secretase directly sheds the survival receptor BCMA from plasma cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84931291652",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "7333"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "SA",
                                        "@_fa": "true",
                                        "ce:surname": "Laurent",
                                        "ce:indexed-name": "Laurent SA"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "FS",
                                        "@_fa": "true",
                                        "ce:surname": "Hoffmann",
                                        "ce:indexed-name": "Hoffmann FS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "PH",
                                        "@_fa": "true",
                                        "ce:surname": "Kuhn",
                                        "ce:indexed-name": "Kuhn PH"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Commun"
                        },
                        "ce:source-text": "Laurent SA, Hoffmann FS, Kuhn PH, et al. Î³-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):7333."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Cowan AJ, Pont M, Sather BD, et al Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(suppl 1):204.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084381570",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "204"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "AJ",
                                        "@_fa": "true",
                                        "ce:surname": "Cowan",
                                        "ce:indexed-name": "Cowan AJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Pont",
                                        "ce:indexed-name": "Pont M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "BD",
                                        "@_fa": "true",
                                        "ce:surname": "Sather",
                                        "ce:indexed-name": "Sather BD"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Cowan AJ, Pont M, Sather BD, et al Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(suppl 1):204."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84988805188",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "355"
                                },
                                "pagerange": {"@first": "355ra116"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "CJ",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle CJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "LA",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi LA"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger C"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains [published correction appears in Nat Commun. 2020;11(1):1319]. Nat Commun. 2020;11(1):283.",
                        "@id": "26",
                        "ref-info": {
                            "ref-title": {"ref-titletext": "Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains [published correction appears in Nat Commun. 2020;11(1):1319]"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85081631122",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "283"}
                            },
                            "ref-text": "2020",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N",
                                    "@_fa": "true",
                                    "ce:surname": "Lam",
                                    "ce:indexed-name": "Lam N"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "ND",
                                    "@_fa": "true",
                                    "ce:surname": "Trinklein",
                                    "ce:indexed-name": "Trinklein ND"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B",
                                    "@_fa": "true",
                                    "ce:surname": "Buelow",
                                    "ce:indexed-name": "Buelow B"
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "GH",
                                    "@_fa": "true",
                                    "ce:surname": "Patterson",
                                    "ce:indexed-name": "Patterson GH"
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "N",
                                    "@_fa": "true",
                                    "ce:surname": "Ojha",
                                    "ce:indexed-name": "Ojha N"
                                },
                                {
                                    "@seq": "6",
                                    "ce:initials": "JN.",
                                    "@_fa": "true",
                                    "ce:surname": "Kochenderfer",
                                    "ce:indexed-name": "Kochenderfer JN."
                                }
                            ]},
                            "ref-sourcetitle": "Nat Commun"
                        },
                        "ce:source-text": "Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains [published correction appears in Nat Commun. 2020;11(1):1319]. Nat Commun. 2020;11(1):283."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Smith EL, Staehr M, Masakayan R, et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther. 2018;26(6):1447-1456.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85045572581",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1447",
                                    "@last": "1456"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EL",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith EL"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Staehr",
                                        "ce:indexed-name": "Staehr M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Masakayan",
                                        "ce:indexed-name": "Masakayan R"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mol Ther"
                        },
                        "ce:source-text": "Smith EL, Staehr M, Masakayan R, et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther. 2018;26(6):1447-1456."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1): 160-172.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Targeting the bone marrow microenvironment in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84929323078",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "263",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "160",
                                    "@last": "172"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y",
                                        "@_fa": "true",
                                        "ce:surname": "Kawano",
                                        "ce:indexed-name": "Kawano Y"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Moschetta",
                                        "ce:indexed-name": "Moschetta M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Manier",
                                        "ce:indexed-name": "Manier S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Immunol Rev"
                        },
                        "ce:source-text": "Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1): 160-172."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Sakemura R, Cox MJ, Hansen MJ, et al. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma. Blood. 2019;134(suppl 1): 865.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85097906736",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "865"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Sakemura",
                                        "ce:indexed-name": "Sakemura R"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MJ",
                                        "@_fa": "true",
                                        "ce:surname": "Cox",
                                        "ce:indexed-name": "Cox MJ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "MJ",
                                        "@_fa": "true",
                                        "ce:surname": "Hansen",
                                        "ce:indexed-name": "Hansen MJ"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Sakemura R, Cox MJ, Hansen MJ, et al. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma. Blood. 2019;134(suppl 1): 865."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847-856.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85053082722",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "847",
                                    "@last": "856"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Rafiq",
                                        "ce:indexed-name": "Rafiq S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "OO",
                                        "@_fa": "true",
                                        "ce:surname": "Yeku",
                                        "ce:indexed-name": "Yeku OO"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "HJ",
                                        "@_fa": "true",
                                        "ce:surname": "Jackson",
                                        "ce:indexed-name": "Jackson HJ"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Biotechnol"
                        },
                        "ce:source-text": "Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847-856."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Suarez ER, Chang K, Sun J, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341-34355.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84973640899",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "34341",
                                    "@last": "34355"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "ER",
                                        "@_fa": "true",
                                        "ce:surname": "Suarez",
                                        "ce:indexed-name": "Suarez ER"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Chang",
                                        "ce:indexed-name": "Chang K"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Sun",
                                        "ce:indexed-name": "Sun J"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Oncotarget"
                        },
                        "ce:source-text": "Suarez ER, Chang K, Sun J, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341-34355."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028852213",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "10541"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "OO",
                                    "@_fa": "true",
                                    "ce:surname": "Yeku",
                                    "ce:indexed-name": "Yeku OO"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "TJ",
                                    "@_fa": "true",
                                    "ce:surname": "Purdon",
                                    "ce:indexed-name": "Purdon TJ"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M",
                                    "@_fa": "true",
                                    "ce:surname": "Koneru",
                                    "ce:indexed-name": "Koneru M"
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "D",
                                    "@_fa": "true",
                                    "ce:surname": "Spriggs",
                                    "ce:indexed-name": "Spriggs D"
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "RJ.",
                                    "@_fa": "true",
                                    "ce:surname": "Brentjens",
                                    "ce:indexed-name": "Brentjens RJ."
                                }
                            ]},
                            "ref-sourcetitle": "Sci Rep"
                        },
                        "ce:source-text": "Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Zhang C, Peng Y, Hublitz P, Zhang H, Dong T. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Sci Rep. 2018;8(1):5549.",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85044930247",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "5549"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C",
                                    "@_fa": "true",
                                    "ce:surname": "Zhang",
                                    "ce:indexed-name": "Zhang C"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "Y",
                                    "@_fa": "true",
                                    "ce:surname": "Peng",
                                    "ce:indexed-name": "Peng Y"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "P",
                                    "@_fa": "true",
                                    "ce:surname": "Hublitz",
                                    "ce:indexed-name": "Hublitz P"
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "H",
                                    "@_fa": "true",
                                    "ce:surname": "Zhang",
                                    "ce:indexed-name": "Zhang H"
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Dong",
                                    "ce:indexed-name": "Dong T."
                                }
                            ]},
                            "ref-sourcetitle": "Sci Rep"
                        },
                        "ce:source-text": "Zhang C, Peng Y, Hublitz P, Zhang H, Dong T. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Sci Rep. 2018;8(1):5549."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85018998407",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "737"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "LJ",
                                        "@_fa": "true",
                                        "ce:surname": "Rupp",
                                        "ce:indexed-name": "Rupp LJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Schumann",
                                        "ce:indexed-name": "Schumann K"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "KT",
                                        "@_fa": "true",
                                        "ce:surname": "Roybal",
                                        "ce:indexed-name": "Roybal KT"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Rep"
                        },
                        "ce:source-text": "Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "CRISPR-engineered T cells in patients with refractory cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85080829577",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "367",
                                    "@issue": "6481"
                                },
                                "pagerange": {"@first": "eaba7365"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EA",
                                        "@_fa": "true",
                                        "ce:surname": "Stadtmauer",
                                        "ce:indexed-name": "Stadtmauer EA"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "JA",
                                        "@_fa": "true",
                                        "ce:surname": "Fraietta",
                                        "ce:indexed-name": "Fraietta JA"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "MM",
                                        "@_fa": "true",
                                        "ce:surname": "Davis",
                                        "ce:indexed-name": "Davis MM"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Science"
                        },
                        "ce:source-text": "Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Works M, Soni N, Hauskins C, et al. Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol Cancer Ther. 2019;18(12):2246-2257.",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85075454901",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "18",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "2246",
                                    "@last": "2257"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Works",
                                        "ce:indexed-name": "Works M"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Soni",
                                        "ce:indexed-name": "Soni N"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Hauskins",
                                        "ce:indexed-name": "Hauskins C"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mol Cancer Ther"
                        },
                        "ce:source-text": "Works M, Soni N, Hauskins C, et al. Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol Cancer Ther. 2019;18(12):2246-2257."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res. 2018;24(1):106-119.",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85040069390",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "106",
                                    "@last": "119"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang X"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Walter",
                                        "ce:indexed-name": "Walter M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Urak",
                                        "ce:indexed-name": "Urak R"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res. 2018;24(1):106-119."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Sadelain M, RiviÃ¨re I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423-431.",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Therapeutic T cell engineering"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85019723531",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "545",
                                    "@issue": "7655"
                                },
                                "pagerange": {
                                    "@first": "423",
                                    "@last": "431"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M",
                                    "@_fa": "true",
                                    "ce:surname": "Sadelain",
                                    "ce:indexed-name": "Sadelain M"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "I",
                                    "@_fa": "true",
                                    "ce:surname": "RiviÃ¨re",
                                    "ce:indexed-name": "Riviere I"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Riddell",
                                    "ce:indexed-name": "Riddell S."
                                }
                            ]},
                            "ref-sourcetitle": "Nature"
                        },
                        "ce:source-text": "Sadelain M, RiviÃ¨re I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423-431."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928-933.",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84885612102",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "928",
                                    "@last": "933"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Themeli",
                                        "ce:indexed-name": "Themeli M"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "CC",
                                        "@_fa": "true",
                                        "ce:surname": "Kloss",
                                        "ce:indexed-name": "Kloss CC"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Ciriello",
                                        "ce:indexed-name": "Ciriello G"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Biotechnol"
                        },
                        "ce:source-text": "Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928-933."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Bjordahl R, Gaidarova S, Goodridge JP, et al. FT576: a novel multiplexed engineered off-the-shelf natural killer cell immunotherapy for the dual-targeting of CD38 and Bcma for the treatment of multiple myeloma. Blood. 2019;134(suppl 1):3214.",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "FT576: a novel multiplexed engineered off-the-shelf natural killer cell immunotherapy for the dual-targeting of CD38 and Bcma for the treatment of multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85092481911",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "3214"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Bjordahl",
                                        "ce:indexed-name": "Bjordahl R"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Gaidarova",
                                        "ce:indexed-name": "Gaidarova S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "JP",
                                        "@_fa": "true",
                                        "ce:surname": "Goodridge",
                                        "ce:indexed-name": "Goodridge JP"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Bjordahl R, Gaidarova S, Goodridge JP, et al. FT576: a novel multiplexed engineered off-the-shelf natural killer cell immunotherapy for the dual-targeting of CD38 and Bcma for the treatment of multiple myeloma. Blood. 2019;134(suppl 1):3214."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175-180.",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "CAR-NK for tumor immunotherapy: clinical transformation and future prospects"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85077389158",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "472"},
                                "pagerange": {
                                    "@first": "175",
                                    "@last": "180"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "W",
                                    "@_fa": "true",
                                    "ce:surname": "Wang",
                                    "ce:indexed-name": "Wang W"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J",
                                    "@_fa": "true",
                                    "ce:surname": "Jiang",
                                    "ce:indexed-name": "Jiang J"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Wu",
                                    "ce:indexed-name": "Wu C."
                                }
                            ]},
                            "ref-sourcetitle": "Cancer Lett"
                        },
                        "ce:source-text": "Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175-180."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Garfall AL, Dancy EK, Cohen AD, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812-2815.",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85073423205",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "2812",
                                    "@last": "2815"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "AL",
                                        "@_fa": "true",
                                        "ce:surname": "Garfall",
                                        "ce:indexed-name": "Garfall AL"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "EK",
                                        "@_fa": "true",
                                        "ce:surname": "Dancy",
                                        "ce:indexed-name": "Dancy EK"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "AD",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen AD"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Garfall AL, Dancy EK, Cohen AD, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812-2815."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571.",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85046093409",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "563",
                                    "@last": "571"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JA",
                                        "@_fa": "true",
                                        "ce:surname": "Fraietta",
                                        "ce:indexed-name": "Fraietta JA"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "SF",
                                        "@_fa": "true",
                                        "ce:surname": "Lacey",
                                        "ce:indexed-name": "Lacey SF"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "EJ",
                                        "@_fa": "true",
                                        "ce:surname": "Orlando",
                                        "ce:indexed-name": "Orlando EJ"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Kravets VG, Zhang Y, Sun H. Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy. J Immunol Res Ther. 2017;2(1):100-113.",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85087003685",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "2",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "100",
                                    "@last": "113"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "VG",
                                    "@_fa": "true",
                                    "ce:surname": "Kravets",
                                    "ce:indexed-name": "Kravets VG"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "Y",
                                    "@_fa": "true",
                                    "ce:surname": "Zhang",
                                    "ce:indexed-name": "Zhang Y"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Sun",
                                    "ce:indexed-name": "Sun H."
                                }
                            ]},
                            "ref-sourcetitle": "J Immunol Res Ther"
                        },
                        "ce:source-text": "Kravets VG, Zhang Y, Sun H. Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy. J Immunol Res Ther. 2017;2(1):100-113."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Gregory T, Cohen AD, Costello CL, et al. Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (mm). Blood. 2018;132(suppl 1):1012.",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (mm)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062349921",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "132"},
                                "pagerange": {"@first": "1012"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Gregory",
                                        "ce:indexed-name": "Gregory T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AD",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen AD"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "CL",
                                        "@_fa": "true",
                                        "ce:surname": "Costello",
                                        "ce:indexed-name": "Costello CL"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Gregory T, Cohen AD, Costello CL, et al. Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (mm). Blood. 2018;132(suppl 1):1012."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500.",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84959328185",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "492",
                                    "@last": "500"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Sommermeyer",
                                        "ce:indexed-name": "Sommermeyer D"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Hudecek",
                                        "ce:indexed-name": "Hudecek M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "PL",
                                        "@_fa": "true",
                                        "ce:surname": "Kosasih",
                                        "ce:indexed-name": "Kosasih PL"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020; 38(15 suppl):8504.",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85087663319",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "8504"}
                            },
                            "ref-text": "(suppl)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Mailankody",
                                        "ce:indexed-name": "Mailankody S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AJ",
                                        "@_fa": "true",
                                        "ce:surname": "Jakubowiak",
                                        "ce:indexed-name": "Jakubowiak AJ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Htut",
                                        "ce:indexed-name": "Htut M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020; 38(15 suppl):8504."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Feucht J, Sun J, Eyquem J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency [published correction appears in Nat Med. 2019;25(3):530]. Nat Med. 2019;25(1):82-88.",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency [published correction appears in Nat Med. 2019;25(3):530]"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85058853412",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "82",
                                    "@last": "88"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Feucht",
                                        "ce:indexed-name": "Feucht J"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Sun",
                                        "ce:indexed-name": "Sun J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Eyquem",
                                        "ce:indexed-name": "Eyquem J"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Feucht J, Sun J, Eyquem J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency [published correction appears in Nat Med. 2019;25(3):530]. Nat Med. 2019;25(1):82-88."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017; 543(7643):113-117.",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014564234",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "543",
                                    "@issue": "7643"
                                },
                                "pagerange": {
                                    "@first": "113",
                                    "@last": "117"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Eyquem",
                                        "ce:indexed-name": "Eyquem J"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Mansilla-Soto",
                                        "ce:indexed-name": "Mansilla-Soto J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Giavridis",
                                        "ce:indexed-name": "Giavridis T"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nature"
                        },
                        "ce:source-text": "Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017; 543(7643):113-117."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Berdeja JG, Madduri D, Usmani SZ, et al. Update of CARTITUDE-1: a phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CART-cell therapy, in relapsed/refractory multiple myeloma. J Clin Oncol. 2020;38(15 suppl):8505.",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Update of CARTITUDE-1: a phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CART-cell therapy, in relapsed/refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85089336565",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "8505"}
                            },
                            "ref-text": "(suppl)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JG",
                                        "@_fa": "true",
                                        "ce:surname": "Berdeja",
                                        "ce:indexed-name": "Berdeja JG"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Madduri",
                                        "ce:indexed-name": "Madduri D"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "SZ",
                                        "@_fa": "true",
                                        "ce:surname": "Usmani",
                                        "ce:indexed-name": "Usmani SZ"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Berdeja JG, Madduri D, Usmani SZ, et al. Update of CARTITUDE-1: a phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CART-cell therapy, in relapsed/refractory multiple myeloma. J Clin Oncol. 2020;38(15 suppl):8505."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Jie J, Hao S, Jiang S, et al. Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed/refractory multiple myeloma. Blood. 2019;134(suppl 1):4435.",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed/refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85078609164",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "4435"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Jie",
                                        "ce:indexed-name": "Jie J"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Hao",
                                        "ce:indexed-name": "Hao S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Jiang",
                                        "ce:indexed-name": "Jiang S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Jie J, Hao S, Jiang S, et al. Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed/refractory multiple myeloma. Blood. 2019;134(suppl 1):4435."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.181",
                        "ref-fulltext": "Li C, Wang J, Wang D, et al. Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed/refractory multiple myeloma. Blood. 2019;134(suppl 1):929.",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed/refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85078597469",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "929"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li C"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang D"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Li C, Wang J, Wang D, et al. Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed/refractory multiple myeloma. Blood. 2019;134(suppl 1):929."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85097310758",
        "dc:description": "Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall response rates in this difficult-to-treat patient population. However, a significant proportion of patients ultimately relapse despite achieving deep remission. Several innovative approaches, including alternative/dual-antigen-specific CAR T-cell constructs, genetically engineered \u201coff-the-shelf\u201d CAR T cells, and strategies to counteract an immunosuppressive microenvironment, may dramatically reshape the field of CAR T-cell therapy in the future. These strategies are being actively investigated in preclinical and early clinical trial settings with the hopes of enhancing the durability of responses and, thereby, improving the overall survival of RRMM patients after CAR T-cell therapy.",
        "pubmed-id": "33275747",
        "prism:coverDate": "2020-12-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85097310758",
        "dc:creator": {"author": [{
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60028190",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85097310758"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097310758&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85097310758&origin=inward"
            }
        ],
        "source-id": "25981",
        "citedby-count": "19",
        "prism:volume": "20",
        "subtype": "ar",
        "dc:title": "Future of CAR T cells in multiple myeloma",
        "openaccess": "1",
        "prism:issn": "15204383 15204391",
        "publishercopyright": "Â© 2020 American Society of Hematology. All rights reserved.",
        "prism:issueIdentifier": "1",
        "subtypeDescription": "Article",
        "prism:publicationName": "Hematology (United States)",
        "prism:pageRange": "272-279",
        "prism:endingPage": "279",
        "openaccessFlag": "true",
        "prism:doi": "10.1182/HEMATOLOGY.2020000111",
        "prism:startingPage": "272",
        "dc:identifier": "SCOPUS_ID:85097310758",
        "dc:publisher": "American Society of Hematology"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Aged",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunotherapy, Adoptive",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Multiple Myeloma",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Receptors, Chimeric Antigen",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Recurrence",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Treatment Failure",
            "@weight": "a",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": null,
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Hematology",
        "@code": "2720",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60028190",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        },
        {
            "ce:given-name": "Sham",
            "preferred-name": {
                "ce:given-name": "Sham",
                "ce:initials": "S.",
                "ce:surname": "Mailankody",
                "ce:indexed-name": "Mailankody S."
            },
            "@seq": "2",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Mailankody",
            "@auid": "36008881400",
            "author-url": "https://api.elsevier.com/content/author/author_id/36008881400",
            "ce:indexed-name": "Mailankody S."
        },
        {
            "ce:given-name": "Eric L.",
            "preferred-name": {
                "ce:given-name": "Eric L.",
                "ce:initials": "E.L.",
                "ce:surname": "Smith",
                "ce:indexed-name": "Smith E.L."
            },
            "@seq": "3",
            "ce:initials": "E.L.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002746",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746"
            },
            "ce:surname": "Smith",
            "@auid": "35448715000",
            "author-url": "https://api.elsevier.com/content/author/author_id/35448715000",
            "ce:indexed-name": "Smith E.L."
        }
    ]}
}}